In 2016, North America and Europe are expected to be the mature markets for HLA typing products for transplant. However, emerging regions such as Asia-Pacific (including Japan, China, and India) are expected to become the new revenue-generating pockets in the HLA typing for transplant market in the next five years. The North America is expected to hold the largest share of the global HLA typing for transplant market in 2016; it is projected to grow at the highest CAGR during the forecast period owing to easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, increasing prevalence of target diseases (such as cancer, heart failure, and renal diseases) in the U.S. and Canada, and continuous technological advancements in the field of HLA-based transplant diagnostics.
For More Information : http://www.marketsandmarkets.com/pdfdownload.asp?id=96374742
Europe is expected to hold the second-largest share of the global HLA typing for transplant market in 2016. This leading market position of the European market is due to factors such as rising acceptance of genome-based diagnostic techniques by healthcare professionals, large number of organ transplantation procedures performed annually, presence of a large number of biotechnology and molecular diagnostic companies, and rapid growth in the aging population.
Thermo Fisher Scientific, Inc. (U.S.) dominated the global HLA typing for transplant market with a share of 42.0% in 2015. In the past three years, the company adopted strategic acquisitions and geographic expansions as key growth strategies to maintain its dominant position in the global transplant diagnostics market. Other leading players present in the HLA typing for transplant market are Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others.
The global HLA typing for transplant market is projected to reach USD 753.9 Million by 2021 from USD 535.0 Million in 2016, at a CAGR of 7.1% from 2016 to 2021.
For More Information : http://www.marketsandmarkets.com/pdfdownload.asp?id=96374742
Europe is expected to hold the second-largest share of the global HLA typing for transplant market in 2016. This leading market position of the European market is due to factors such as rising acceptance of genome-based diagnostic techniques by healthcare professionals, large number of organ transplantation procedures performed annually, presence of a large number of biotechnology and molecular diagnostic companies, and rapid growth in the aging population.
Thermo Fisher Scientific, Inc. (U.S.) dominated the global HLA typing for transplant market with a share of 42.0% in 2015. In the past three years, the company adopted strategic acquisitions and geographic expansions as key growth strategies to maintain its dominant position in the global transplant diagnostics market. Other leading players present in the HLA typing for transplant market are Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others.
The global HLA typing for transplant market is projected to reach USD 753.9 Million by 2021 from USD 535.0 Million in 2016, at a CAGR of 7.1% from 2016 to 2021.
No comments:
Post a Comment